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A 40-year-old woman who recently received a diagnosis of Graves’ disease comes for 
a follow-up visit. She has been taking methimazole, at a dose of 10 mg daily, and is 
now euthyroid, but for the past 3 months, she has had bothersome eye symptoms, 
including redness, tearing, grittiness, photophobia, diplopia at the extremes of gaze, 
and ocular pain with eye movements. She smokes 10 cigarettes per day. Examination 
reveals exophthalmos, swelling of periorbital tissues, and limitation of eye move-
ments. How should Graves’ ophthalmopathy be managed?
The Clinic a l Problem
Graves’ disease is often characterized by ocular manifestations of autoimmune 
origin, so-called Graves’ orbitopathy or ophthalmopathy.1 The clinical features and 
management of Graves’ hyperthyroidism have recently been reviewed in the Jour-
nal1; this article focuses on Graves’ ophthalmopathy.
A detailed discussion of the pathogenesis of Graves’ ophthalmopathy is beyond 
the scope of this article, but it has been reviewed elsewhere.2,3 Patients with 
Graves’ ophthalmopathy are not necessarily hyperthyroid; a minority of patients 
(less than 10%) are euthyroid or hypothyroid.4 Graves’ ophthalmopathy is probably 
initiated by autoreactive T lymphocytes reacting with one or more antigens shared 
by the thyroid and orbit; after reaching the orbit and recognizing the shared anti-
gen (or antigens), T lymphocytes trigger a cascade of events, including secretion 
of cytokines.4 These cytokines stimulate the proliferation of orbital fibroblasts, ex-
pansion of adipose tissue, and secretion of hydrophilic glycosaminoglycans from 
fibroblasts. The resulting increase in orbital content explains many manifestations 
of Graves’ ophthalmopathy.5 B cells are also involved as antigen-presenting and 
autoantibody-producing cells.6 The thyrotropin receptor,7 the insulin-like growth 
factor I receptor,8 or both might be the elusive shared autoantigens. Genetic de-
terminants of Graves’ ophthalmopathy remain poorly understood. Environmental 
factors appear to play a major role in the development and progression of Graves’ 
ophthalmopathy.9,10
Case series from referral centers indicate that clinically recognized Graves’ oph-
thalmopathy occurs in about 50% of cases of Graves’ disease, is clinically relevant 
in 20 to 30%, and is sight-threatening (because of dysthyroid optic neuropathy, 
corneal breakdown, or both) in 3 to 5%.9 Even in the absence of clinical manifes-
tations, imaging reveals subtle orbital changes in most patients. Common bother-
some symptoms, including diplopia and symptoms related to corneal exposure, such 
as photophobia, tearing, grittiness, and pain, may interfere with daily activities. 
In a cohort study, rates of eyelid retraction, exophthalmos, extraocular muscle dys-
function, ocular pain, and lacrimation were 91%, 62%, 43%, 30%, and 23%, respec-
tively; optic-nerve dysfunction was detected in only 6% of patients.11 Even mild ocu-
This Journal feature begins with a case vignette highlighting a common clinical problem.  
Evidence supporting various strategies is then presented, followed by a review of formal guidelines,  
when they exist. The article ends with the authors’ clinical recommendations. 
An audio version 
of this article 
is available at 
NEJM.org
clinical pr actice
n engl j med 360;10 nejm.org march 5, 2009 995
lar changes (e.g., lid retraction, mild exophthalmos, 
swelling of periorbital tissues, and fixed gaze) 
(Fig. 1) pose cosmetic problems and may hamper 
social relationships.12
The natural history of Graves’ ophthalmopathy 
is variable; ocular symptoms may progress, remain 
unchanged, or improve spontaneously.13 Generally, 
there is an initial inflammatory phase (the active 
phase) lasting 1 to 2 years, followed by stabiliza-
tion (the plateau phase), and eventually, remission 
(the inactive phase) occurs, but it is incomplete.9
S tr ategies a nd E v idence
Diagnosis
Graves’ ophthalmopathy is usually bilateral, but 
it can be asymmetric or unilateral.4 This condition 
often develops concomitantly with hyperthyroid-
ism, but it may precede or follow hyperthyroid-
ism.9 Although the diagnosis is straightforward 
in patients with hyperthyroidism and bilateral 
ophthalmopathy, it should also be considered in 
patients with no thyroid dysfunction and those 
in whom ophthalmopathy is unilateral. Several 
other conditions may cause unilateral or bilateral 
exophthalmos or extraocular muscle enlargement. 
These conditions include Cushing’s syndrome, obe-
sity, orbital pseudotumor, idiopathic myositis and 
cellulitis, primary or metastatic orbital tumors, 
fistulas in the cavernous portion of the carotid 
artery and other vascular conditions, and granu-
lomatous disorders. When the diagnosis is un-
certain, orbital imaging with the use of computed 
tomography (CT) or magnetic resonance imaging 
(MRI) is warranted, and measurement of thyrotro-
pin-receptor antibodies may have diagnostic val-
ue as well because of their high specificity and 
sensitivity for Graves’ disease. Orbital imaging in 
patients with Graves’ ophthalmopathy shows en-
largement of the extraocular muscles (with ten-
don sparing), an increase in orbital fibroadipose 
tissue, or both (Fig. 2). When dysthyroid optic 
neuropathy is suspected because of reduced vi-16p6
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Figure 1. Clinical Features of Graves’ Ophthalmopathy.
Panel A shows a man with bilateral exophthalmos and 
marked retraction of the upper eyelid. Panel B shows 
a woman with mild inflammatory signs and hypotro-
pia in the right eye. Panel C shows a woman with 
marked edema and redness in the upper eyelid, red-
ness of the conjunctiva, and severe chemosis in the 
left eye. Panel D shows a man with marked edema 
and retraction of the eyelid and exophthalmos. Panel 
E shows a woman with marked redness of the con-
junctiva and chemosis. There is marked impairment of 
movement of the globes, which are unable to follow 
the examiner’s finger; this patient had severe dysthy-
roid optic neuropathy, which responded dramatically 
to intravenous glucocorticoids.
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sual acuity, visual-field defects, and reduced color 
sensitivity, imaging may also reveal optic-nerve 
compression by the enlarged muscles, particularly 
at the orbital apex; this is called apical crowding.
Evaluation
Because the treatment for Graves’ ophthalmopa-
thy varies according to the level of its activity 
(i.e., active disease tends to respond to immuno-
suppressive therapy, whereas inactive disease does 
not),14,15 methods have been proposed to deter-
mine whether Graves’ ophthalmopathy is active. 
Although no method is both specific and com-
pletely reliable, a simple office-based tool is the 
Clinical Activity Score,16 which reflects the pres-
ence or absence of seven symptoms or signs that 
indicate inflammation (Table 1). One point is as-
signed to each symptom or sign that is present; a 
Clinical Activity Score of 3 or more indicates ac-
tive Graves’ ophthalmopathy.14,15 Although im-
perfect, this score has been shown to be predic-
tive of a patient’s response to immunosuppressive 
therapy.16,17
In addition, the severity of disease should be 
assessed by measuring exophthalmos and lid 
width, evaluating soft-tissue involvement and ex-
traocular muscle function, and assessing corneal 
involvement and optic-nerve involvement14,15 (Ta-
ble 2). Dysthyroid optic neuropathy, corneal break-
down, or both indicate that the Graves’ oph-
thalmopathy is sight-threatening and requires 
immediate treatment.14,15 The most frequent fea-
tures of dysthyroid optic neuropathy include 
swelling of the optic disk, impaired color vision, 
radiologic evidence of apical crowding, and de-
creased visual acuity; marked exophthalmos and 
severe orbital inflammation may be absent.18
Patients with Graves’ ophthalmopathy should 
be evaluated and treated by both an endocrinolo-
gist and an ophthalmologist with expertise in this 
disorder. Referral is urgent if dysthyroid optic 
neuropathy is suspected because of deterioration 
of vision, changes in the intensity or quality of 
color vision, or disk swelling on funduscopy, or if 
there is globe subluxation, corneal opacity, or lag-
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Figure 2. CT of the Orbits in Two Patients with Graves’ 
Ophthalmopathy. 
In one patient, coronal sections (Panel A) show marked 
enlargement of the medial rectus and inferior rectus 
muscles bilaterally; the optic nerves (arrows) are not 
compressed by the enlarged muscles. In the other pa-
tient, sagittal sections (Panel B) show exophthalmos, 
the enlarged medial rectus, and the inferior rectus 
muscles; Panel C shows the results in this patient after 
intra venous glucocorticoid therapy. The exophthalmos 
is reduced, and the volume of the affected muscles is 
 decreased.
Table 1. Components of the Clinical Activity Score.*
Spontaneous retrobulbar pain
Pain with eye movement
Redness of the eyelids
Redness of the conjunctiva
Swelling of the eyelids
Swelling of the caruncle
Conjunctival edema (chemosis)
* The Clinical Activity Score is calculated according to the 
presence or absence of the characteristics listed. The 
score ranges from 0 to 7, with 0 to 2 characteristics indi-
cating inactive Graves’ ophthalmopathy and 3 to 7 char-
acteristics indicating active Graves’ ophthalmopathy. 
Data are from Mourits et al.16
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ophthalmos (incomplete closure of the palpebral 
fissure) with visible cornea.19 In all cases, selec-
tion of the appropriate treatment depends on a 
detailed evaluation (Table 2). A specialized eval-
uation is recommended early in the disease pro-
cess, given evidence that the outcomes of treat-
ment are best in cases of recent onset (within 12 
to 18 months).20
Management
In all patients with ophthalmopathy, factors as-
sociated with an increased risk of progression of 
ocular disease should be eliminated or controlled. 
For instance, patients who smoke should be en-
couraged to quit. Although data from randomized 
trials are lacking, in one observational study, smok-
ing cessation has been associated with a decreased 
risk of the development of exophthalmos and 
diplopia in patients with Graves’ disease.21
Thyroid dysfunction (both hyperthyroidism and 
hypothyroidism) should be corrected.10 In a pro-
spective observational study, restoration of euthy-
roidism by antithyroid drugs was associated with 
an amelioration of Graves’ ophthalmopathy.22 In 
randomized trials, radioiodine therapy for Graves’ 
hyperthyroidism caused progression of ophthal-
mopathy in about 15% of patients,23,24 whereas 
antithyroid drugs did not modify the natural 
course of Graves’ ophthalmopathy.24 Risk factors 
for progression of Graves’ ophthalmopathy after 
radioiodine therapy include cigarette smoking,25 
severe hyperthyroidism (serum triiodothyronine 
concentration, ≥5 nmol per liter),23 high levels of 
thyrotropin-receptor antibodies,26 and uncon-
trolled hypothyroidism after radioiodine thera-
py.27 In two randomized trials, concomitant treat-
ment of high-risk patients with oral prednisone 
(at an initial dose of 0.3 to 0.5 mg per kilogram 
of body weight given 1 to 3 days after radioio-
dine therapy, with tapering of the dose until 
withdrawal 3 months later) prevented progres-
sion and ameliorated preexisting Graves’ ophthal-
mopathy.24,28 
Prophylactic treatment with glucocorticoid 
agents may be appropriate for many patients with 
Graves’ ophthalmopathy whose hyperthyroidism 
is treated with radioiodine therapy, including pa-
tients with active ophthalmopathy or risk factors 
such as those described above.14,15 In a prospective 
observational study, patients who began to receive 
levothyroxine (usually 50 μg per day initially) as 
early as 2 weeks after radioiodine therapy had a 
markedly reduced risk of progression of Graves’ 
ophthalmopathy, as compared with patients in 
whom levothyroxine treatment was not initiated 
until hypothyroidism developed.29 It is unclear 
whether associated hyperthyroidism in patients 
with Graves’ ophthalmopathy should be treated 
with antithyroid drugs or with ablative treatments 
(i.e., thyroidectomy, radioiodine, or both).
Specific treatments for Graves’ ophthalmopathy 
vary depending on the severity of the disease. Mild 
Graves’ ophthalmopathy usually does not require 
any treatment except for local measures (e.g., 
lubricants, ointments, dark lenses, and prisms to 
reduce diplopia) to control mild symptoms and 
signs.14,15 In some instances, however, the patient’s 
quality of life is so impaired that treatment such 
as that for more severe Graves’ ophthalmopathy is 
warranted. Regular follow-up every 3 to 6 months 
is routinely warranted, since progression from 
mild ophthalmopathy to moderate-to-severe dis-
ease occurs in about 25% of patients.13,30
Glucocorticoid Therapy
Patients with sight-threatening dysthyroid optic 
neuropathy require immediate treatment, usually 
with high-dose intravenous or oral glucocorticoid 
agents. Although there is no established treat-
ment schedule, a common initial regimen is the 
administration of 1 g of methylprednisolone in-
travenously for 3 consecutive days.14,15 Subse-
quent treatment depends on the response. If there 
is little or no improvement after 1 to 2 weeks, 
patients should promptly undergo surgical orbital 
decompression.14,15 In a small randomized trial, 
there was no significant difference in outcome be-
Table 2. Features of Mild and Moderate-to-Severe Graves’ Ophthalmopathy.*
Characteristic
Mild Graves’ 
Ophthalmopathy
Moderate-to-Severe 
Graves’  
Ophthalmopathy
Eyelid retraction (mm) <2 ≥2
Exophthalmos (mm) <3 ≥3
Soft-tissue involvement Mild Moderate to severe
Extraocular muscle involve-
ment (diplopia)†
None or intermittent Inconstant or constant
Corneal involvement Absent or mild Moderate
* Data are derived from Bartalena et al.14,15
† Intermittent diplopia occurs when the patient is fatigued or awakening in the 
morning, inconstant diplopia occurs at the extremes of gaze, and constant 
diplopia occurs both when the patient is looking straight ahead and when the 
patient is looking down.
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tween decompression performed as first-line treat-
ment and initial treatment with intravenous glu-
cocorticoids followed by oral prednisone.31
Glucocorticoids are also used for moderate-to-
severe and active ophthalmopathy.9 In a placebo-
controlled, randomized trial, intravenous glu-
cocorticoids (four cycles of methylprednisolone at 
a dose of 500 mg for 3 consecutive days at 4-week 
intervals) were effective in treating inflammatory 
changes and ocular movements in five of six pa-
tients (83%) as compared with one of nine pa-
tients (11%) who received placebo.32 High-dose 
oral glucocorticoids (e.g., prednisolone at a dose 
of 40 mg or more initially) are also commonly 
used33; the dose is then gradually tapered until 
withdrawal after 4 to 6 months. An overall re-
sponse rate of 63% was reported in several case 
series of patients treated with oral glucocorti-
coids.9 Two randomized trials34,35 have shown 
that intravenous therapy results in a higher rate of 
favorable responses than oral therapy (88% vs. 
63% in one study34 and 77% vs. 51% in the oth-
er35), and it is better tolerated, with a reduced risk 
of the development of cushingoid features.34,35 
However, rare cases of severe and acute liver dam-
age (including four that were fatal) have been re-
ported with the use of very high doses.36,37 Thus, 
intravenous therapy should be given only with 
close monitoring (particularly of liver function) 
in specialized centers. There is no consensus re-
garding the optimal dose and schedule, but a 
commonly used regimen consists of 12 weekly 
infusions of methylprednisolone with a cumula-
tive dose of 4.5 g (500 mg weekly for 6 weeks, 
then 250 mg weekly for 6 weeks).35 These doses 
are much lower than those used previously; to 
minimize the risk of hepatotoxicity, courses ex-
ceeding 8 g are not recommended.14,15,38 Oral 
glucocorticoids are a reasonable alternative op-
tion, particularly in patients with liver disease. 
Besides liver abnormalities, patients should be 
closely followed for other potential adverse effects 
of glucocorticoid treatment (e.g., increased blood 
pressure, hyperglycemia, electrolyte abnormalities, 
gastric effects, and infection).
Orbital Radiotherapy
Orbital irradiation may be a useful addition to 
therapy, particularly when eye motility is im-
paired.39 In case series, about 60% of patients 
have had overall favorable responses to orbital ir-
radiation,9 although patients with certain features, 
including exophthalmos, eyelid retraction, and 
soft-tissue changes, tend to have a poor response 
to treatment.40 A common cumulative dose of 
radiation is 20 Gy per eye, given in 10 sessions 
over a 2-week period, but a lower cumulative dose 
(10 Gy) may be equally effective.41 In a random-
ized trial comparing orbital irradiation with oral 
glucocorticoids, the efficacy rates were similar 
with the two approaches (approximately 50%).42 
Data from randomized trials indicate that com-
bined treatment with radiotherapy and oral glu-
cocorticoids is more effective than either treat-
ment alone9; it is not known whether the same is 
true regarding intravenous glucocorticoid thera-
py. Orbital irradiation should be avoided in pa-
tients younger than 35 years of age (because of 
the potential long-term carcinogenic effects) and 
in patients with diabetic retinopathy or severe hy-
pertension (because of possible additional dam-
age to the retina).14,15 To our knowledge, no cases 
of radiation-induced tumors have been reported 
in patients treated with orbital radiotherapy for 
Graves’ ophthalmopathy.
Other Possible Pharmacologic Treatments
Randomized trials have not shown a benefit of 
somatostatin analogues (octreotide and lanreotide) 
for Graves’ ophthalmopathy.43 There are also few 
data to support the use of intravenous immune 
globulin for this condition.43 Cyclosporine, al-
though shown to be less effective than oral glu-
cocorticoids in a randomized trial, may help to 
reduce the dose of glucocorticoids.44 Preliminary 
data suggest that immunomodulating drugs such 
as rituximab45,46 or inhibitors of tumor necrosis 
factor α47 may be beneficial in Graves’ ophthal-
mop athy. In an open-label study, the effects of 
rituximab in patients with Graves’ ophthalmopathy 
were similar to those observed in historical con-
trols treated with intravenous glucocorticoids.46
Surgery
Orbital decompression is required for sight-threat-
ening dysthyroid optic neuropathy if high-dose 
glucocorticoids do not ameliorate this condition 
within 1 to 2 weeks.14,15,31 If vision is threatened 
by imminent corneal breakdown (which is usually 
associated with severe exophthalmos and lagoph-
thalmos), and local measures and eyelid closure 
do not provide rapid, substantial improvement, 
orbital decompression is indicated to improve ex-
posure keratopathy.14,15 Orbital surgery (includ-
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ing eye-muscle surgery to correct extraocular mus-
cle dysfunction and eyelid surgery to correct eyelid 
retraction) may reduce the disfigurement caused 
by Graves’ ophthalmopathy.48 Surgery should be 
performed after ophthalmopathy has been con-
sistently inactive for at least 6 months.14,15 Or-
bital decompression can be performed by means 
of a variety of surgical techniques that are de-
scribed in detail elsewhere.49 If multiple surgical 
procedures are required for stably inactive Graves’ 
ophthalmopathy, orbital decompression should 
be performed first, followed by strabismus surgery 
and, finally, eyelid surgery.14,15 Such rehabilitative 
surgery can be carried out in cases of long-stand-
ing Graves’ ophthalmopathy.50
A r e a s of Uncerta in t y
The appropriate use of radioiodine therapy for 
managing hyperthyroidism in patients with Graves’ 
ophthalmopathy remains uncertain. Some experts 
recommend that antithyroid drugs be used as 
first-line treatment in patients with active oph-
thalmopathy,51 with the use of radioiodine thera-
py only later, when Graves’ ophthalmopathy is 
inactive and if antithyroid drug treatment fails. 
Results of a randomized trial comparing early 
total thyroid ablation (thyroidectomy followed by 
radioiodine therapy) with near-total thyroidectomy 
in patients with mild-to-moderate Graves’ oph-
thalmopathy treated with intravenous glucocorti-
coids suggested that total ablation results in better 
outcomes, although differences between groups 
were clinically modest.52
In patients who have received radioiodine 
therapy, oral glucocorticoid prophylaxis usually is 
recommended, but the timing of initiation and 
the optimal dose and duration are uncertain. The 
efficacy of prophylactic treatment for less than 
3 months with lower doses of prednisone and 
longer, higher-dose treatment may be similar.
Although there is evidence to support the use 
of intravenous rather than oral glucocorticoid 
therapy for active Graves’ ophthalmopathy, the 
optimal glucocorticoid regimen remains uncer-
tain. It is unclear whether the addition of orbital 
irradiation to intravenous glucocorticoid therapy 
improves outcomes over glucocorticoid therapy 
alone. Randomized trials are lacking to compare 
early treatment with drugs acting on the patho-
genic mechanisms of the disease (such as ritux-
imab) with current standard therapies.
Guidelines 
To our knowledge, no guidelines from professional 
societies on the management of Graves’ ophthal-
mopathy are available. The European Group on 
Graves’ Orbitopathy, a consortium of experts (en-
docrinologists and ophthalmologists) from eight 
European countries, recently published a consen-
sus statement on the management of Graves’ oph-
thalmopathy14,15; since there are few randomized 
trials, this document is based largely on expert 
opinion. The present recommendations are largely 
consistent with those in this statement.
Conclusions a nd 
R ecommendations
The patient described in the vignette has Graves’ 
hyperthyroidism and moderate-to-severe and ac-
tive ophthalmopathy of recent onset. A thorough 
eye evaluation is needed, preferably in a special-
ized center or by both an endocrinologist and an 
ophthalmologist experienced in the management 
of this disorder. Orbital CT and MRI provide use-
ful information regarding extraocular muscle in-
volvement and possible optic-nerve compression. 
Smoking is associated with an increased risk of 
progression of Graves’ ophthalmopathy, and the 
patient should be urged to quit. Artificial tears 
should be prescribed.
Given the patient’s active eye disease, we would 
recommend treatment with intravenous glucocor-
ticoids; oral glucocorticoids are an alternative. In 
the absence of clinically directive evidence con-
cerning the optimal route and dose, we use a 
weekly infusion of methylprednisolone (500 mg 
for the first 6 weeks, followed by six weekly in-
fusions of 250 mg),35 with monitoring of liver-
function tests for other potential adverse effects 
of glucocorticoids. There are no clinically direc-
tive trials to guide treatment, but concomitant use 
of a proton-pump inhibitor and a bisphosphonate 
should be considered, particularly in patients at 
high risk for upper gastrointestinal complications 
or bone loss, respectively. Should ophthalmopa-
thy not improve after 3 to 4 months, we recom-
mend a second course of intravenous glucocorti-
coids with orbital irradiation. An alternative 
treatment to consider is a combination of low-
dose oral prednisone and cyclosporine.43 If oph-
thalmopathy is inactive for at least 6 months, 
rehabilitative surgery (e.g., orbital decompression, 
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strabismus surgery, or eyelid surgery) may be per-
formed in the above order, if needed.
It is important to normalize the patient’s thy-
roid function. Radioiodine therapy carries a risk 
of exacerbation of Graves’ ophthalmopathy; thus, 
we typically prescribe oral glucocorticoid pro-
phylaxis when we use this approach. If we treat 
the patient with intravenous glucocorticoid agents, 
radioiodine therapy is given in the period between 
doses of glucocorticoids. Alternatively, antithyroid 
drug therapy may be continued for an 18-to-24-
month course.
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